Dr John Ford, Chief Executive Officer
Dr John Ford has more than 18 years of ion channel, drug discovery and development experience. As a successful biotechnology entrepreneur he co-founded Xention (CSO), Ario Pharma (CEO) and Metrion Biosciences (co-owner). At Xention he was responsible for the Kv1.5 ion channel atrial fibrillation project which was partnered to Servier (up to 120M EUR). Recently, he was a member of the Executive Team at Dezima (COO) that developed TA-8995 for dyslipidaemia (Phase 2b study published in The Lancet) and sold the company to Amgen ($300M upfront, potential deal size of US$1.55bn + royalties). Previous positions include Team Leader for Receptors and Channel Drug Discovery at BioFocus (now owned by Charles River). Dr Ford holds a BSc and Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.
Prof Martin Gosling, Chief Scientific Officer
Prof Martin Gosling has spent his research career exploiting the therapeutic potential of ion channels in both industrial and academic settings. Prior to co-founding Enterprise Therapeutics, Prof Gosling was Executive Director in the Respiratory Disease Area of the Novartis Institutes for BioMedical Reseach, UK. Whilst with Novartis he established an internal ion channel platform, was a successful Project Team Leader for multiple drug discovery programs and played a lead role in defining the Novartis cystic fibrosis (CF) portfolio. Prof Gosling holds a BSc and PhD in Pharmacology from the Universities of Leeds and Aston respectively. In addition to his position as CSO of Enterprise Therapeutics, he also holds the position of Professor of Molecular Pharmacology at the University of Sussex.
Dr Clive McCarthy, Head of Chemistry
Dr Clive McCarthy obtained his first degree and PhD in chemistry at King’s College London. After postdoctoral research at the University of California, Berkeley, he joined the Discovery Chemistry group at Rhone Poulenc Rorer. During this time he contributed to the discovery of an Endothelin antagonist and inhaled VLA4 antagonist both of which were evaluated in clinical trials. In 2000 he joined Novartis, UK as Chemistry Unit Head. Between 2004 and 2010 he was Director of Chemistry at Novartis, Basel where he lead chemistry teams in hit-lead, CNS and Oncology. In 2011 he joined Evotec as a Research Leader working on projects in Respiratory and Oncology. He has a wide experience in GPCRs, integrins, proteases and particularly kinases. In 2014 he co-founded Enterprise Therapeutics.
Dr Henry Danahay, Head of Biology
Dr Henry Danahay gained a BPharm and PhD from the Welsh School of Pharmacy before joining the Novartis Respiratory Diseases Group. Whilst with Novartis, he worked as an in vitro/in vivo pharmacologist with a specialisation in airway epithelial cell based drug targets. During this time he played a central role in establishing the CF discovery portfolio and was most recently Director and Head of the Lung Repair & Regeneration Group in the Respiratory Disease Area. He has lead a number of drug discovery programs from target identification through to early clinical studies as well as authoring >40 peer reviewed papers and patents. As a co-founder of Enterprise Therapeutics, Dr Danahay is Head of Biology and is an honorary Senior Research Fellow at the University of Sussex.
Dr Phil Boyd, Chief Financial Officer
Dr Phil Boyd was CFO of Syntaxin Ltd from 2007 through to the acquisition by Ipsen in July 2013, and CFO of Tiziana Lifesciences plc (AIM: TILS) from 2014 to 2015. Prior to Syntaxin he was UK Finance Director of Evotec AG (2001-2007) and Cambridge Discovery Chemistry (1999-2001). He currently serves as CFO with Enterprise Therapeutics and Oxford BioDynamics, and as a Non-Executive Director with OBN (UK) Ltd. He has a BSc in Biotechnology and a PhD in Genetics from University of Leeds, and is a qualified management accountant (ACMA).